# US 2008/0306102 A1 · Novel spirooxyindole compounds and drugs containing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306102 A1
- Document ID: US20080306102A1
- Status: Published application
- Kind: A1
- Application number: 12/122,252
- Filed: 2008-05-16
- Published: 2008-12-11
- Earliest claimed: 2007-05-18
- Assignees: Kowa Company, Ltd.
- Inventors: Hisashi NAKASHIMA; Takaaki ARAKI; Takahisa OGAMINO; Yasushi KANEKO; Kazutoyo ABE; Kimiyuki SHIBUYA; Tadaaki OHGIYA
- Web page: https://patentgrep.com/patent/US20080306102A1

## CPC

- C07D 471/10: Spiro-condensed systems
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/12: Antihypertensives
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A Spiro oxindole compound represented by formula (1) of the present invention or salt thereof, or their solvate shows a superior inhibitory effect of 11β-hydroxysteroid dehydrogenasel, and is useful as an agent for preventing or treating a disease that involves 11β-hydroxysteroid dehydrogenasel (in particular, diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome).

## Claims

### Claim 1

A spiro oxindole compound represented by the following general formula (1) or salt thereof, or their solvate:
(wherein A is a —CR12R13—(CH2)n— or —NR14—, B is an oxygen atom, sulfur atom, —NR15—, —CR16R17—, sulfonyl group, sulfinyl group, or —NHCO—CH2— (here, when A is —NR14—, B is —CR16R17—); R0 is a hydrogen atom, alkyl group with 1 to 6 carbon atoms, alkenyl group with 2 to 6 carbon atoms, (aryl with 6 to 14 carbon atoms)-alkyl group with 1 to 6 carbon atoms, cycloalkyl group with 3 to 6 carbon atoms, (cycloalkyl with 3 to 6 carbon atoms)-alkyl group with 1 to 6 carbon atoms, or (5 to 14-membered heteroaryl)-alkyl group with 1 to 6 carbon atoms; each R1, R2, R3, and R4 are same or different and are a hydrogen atom, halogen atom, alkyl group with 1 to 6 carbon atoms, haloalkyl group with 1 to 6 carbon atoms, alkenyl group with 2 to 6 carbon atoms, (alkoxy with 1 to 6 carbon atoms)-alkyl group with 1 to 6 carbon atoms, alkynyl group with 2 to 6 carbon atoms, aryl group with 6 to 14 carbon atoms, aryloxy group with 6 to 14 carbon atoms, cycloalkyl group with 3 to 6 carbon atoms, 5 to 14-membered heteroaryl group, 5 to 14-membered heteroaryloxy group, or 5 to 7-membered heterocycloalkyl group; each R5 and R6 are same or different and are a hydrogen atom, alkyl group with 1 to 6 carbon atoms, haloalkyl group with 1 to 6 carbon atoms, alkenyl-group with 2 to 6 carbon atoms, (alkoxy with 1 to 6 carbon atoms)-alkyl group with 1 to 6 carbon atoms, alkynyl group with 2 to 6 carbon atoms, aryl group with 6 to 14 carbon atoms, aryloxy group with 6 to 14 carbon atoms, cycloalkyl group with 3 to 6 carbon atoms, 5 to 14-membered heteroaryl group, 5 to 14-membered heteroaryloxy group, or 5 to 7-membered heterocycloalkyl group;
each R7, R8, R9, R10, and R11 are same or different and are a hydrogen atom, halogen atom, amino group, cyano group, nitro group, hydroxy group, alkoxy group with 1 to 6 carbon atoms, haloalkoxy group with 1 to 6 carbon atoms, mono- or di-alkylamino group with 1 to 6 carbon atoms, alkyl group with 1 to 6 carbon atoms, haloalkyl group with 1 to 6 carbon atoms, alkenyl group with 2 to 6 carbon atoms, (alkoxy with 1 to 6 carbon atoms)-alkyl group with 1 to 6 carbon atoms, alkynyl group with 2 to 6 carbon atoms, alkylsulfinyl group with 1 to 6 carbon atoms, alkylsulfonyl group with 1 to 6 carbon atoms, aryl group with 6 to 14 carbon atoms, aryloxy group with 6 to 14 carbon atoms, cycloalkyl group with 3 to 6 carbon atoms, 5 to 14-membered heteroaryl group, 5 to 14-membered heteroaryloxy group, or 5 to 7-membered heterocycloalkyl group, or R17 and R8, or R8 and R9 may together form a benzene ring;
when they exist together, each R12, R13, R14, R15, R16, and R17, same or different, are a hydrogen atom, alkyl group with 1 to 6 carbon atoms, haloalkyl group with 1 to 6 carbon atoms, or alkenyl group with 2 to 6 carbon atoms; and
n is an integer of 0 to 10).

### Claim 2 (depends on 1)

A spiro oxindole compound or salt thereof, or their solvate according to claim 1, wherein the compound represented by general formula (1) is:
1′-{2-(2-trifluoromethylphenoxy)acetyl}spiro(indole-3,4′-pi peridine)-2(1H)-one,
1′-{2-(2-methylphenoxy)acetyl}spiro(indole-3,4′-piperidine)-2(1H)-one,
1′-{2-(2-iodophenoxy)acetyl}spiro(indole-3,4′-piperidine)-2 (1H)-one,
1′-{2-(2-nitrophenoxy)acetyl}spiro(indole-3,4′-piperidine)-2(1H)-one,
1′-{2-(2,3-dichlorophenoxy)acetyl}spiro(indole-3,4′-piperid ine)-2(1H)-one,
1′-{2-(2-bromophenoxy)acetyl}spiro(indole-3,4′-piperidine)-2(1H)-one,
1′-{2-(2-t-butylphenoxy)acetyl}spiro(indole-3,4′-piperidine)-2(1H)-one,
1′-{2-(2-trifluoromethylphenylthio)acetyl}spiro(indole-3,4′-piperidine)-2(1H)-one,
1-methyl-1′-{2-(2-trifluoromethylphenoxy)acetyl}spiro(indol e-3,4′-piperidine)-2-one,
1-ethyl-1′-{2-(2-trifluoromethylphenoxy)acetyl}spiro(indole-3,4′-piperidine)-2-one,
1-propyl-1′-{2-(2-trifluoromethylphenoxy)acetyl}spiro(indol e-3,4′-piperidine)-2-one, or
1-cyclopropyl-1′-{2-(2-trifluoromethylphenoxy)acetyl}spiro(indole-3,4′-piperidine)-2-one.

### Claim 3 (depends on 1, 2)

A pharmaceutical composition consisting of the spiro oxindole compound or salt thereof, or their solvate according to claim 1 or 2 and a pharmaceutically acceptable carrier.

### Claim 4 (depends on 1, 2)

An inhibitor of 11β-hydroxysteroid dehydrogenasel, which inhibitor comprises the spiro oxindole compound or salt thereof, or their solvate according to claim 1 or 2 as an active ingredient.

### Claim 5 (depends on 1, 2)

An agent for preventing and/or treating diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome, which agent comprises the spiro oxindole compound or salt thereof, or their solvate according to claim 1 or 2 as an active ingredient.

### Claim 6 (depends on 1, 2)

Use of the spiro oxindole compound or salt thereof, or their solvate according to claim 1 or 2 for producing a formulation for inhibiting 11β-hydroxysteroid dehydrogenasel.

### Claim 7 (depends on 1, 2)

Use of the spiro oxindole compound or salt thereof, or their solvate according to claim 1 or 2 for producing a formulation for an agent for preventing and/or treating diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome.

### Claim 8 (depends on 1, 2)

A method for inhibiting 11β-hydroxysteroid dehydrogenasel, which method comprises administering an effective amount of the spiro oxindole compound or salt thereof, or their solvate according to claim 1 or 2.

### Claim 9 (depends on 1, 2)

A method for preventing and/or treating diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome, which method comprises administering an effective amount of the spiro oxindole compound or salt thereof, or their solvate according to claim 1 or 2.
